Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01516541 · ClinicalTrials.gov registry record · Phase 3
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
A Phase 3 study of Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD), sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,220
- Enrollment target
- 20
- Study locations
NCT01516541: Completed Phase 3 study of Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD), sponsored by Hoffmann-La Roche.
NCT01516541 is a Phase 3 study of Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD) that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2,220 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01516541, a Phase 3 study of Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD), has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular disease. Eligible patients will be randomized to receive either dalcetrapib 600 mg orally daily or placebo orally daily, on a background of contemporary, guidelines-based medical care. Anticipated time on study treatment is 4 years.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER Background care
- DRUG dalcetrapib
Study Locations (20)
California
- - Anaheim
- - Fullerton
- - San Diego
- - Santa Ana
- - Santa Rosa
- - Torrance
- - Torrance
Florida
- - Boynton Beach
- - Daytona Beach
- - Daytona Beach
- - Fort Myers
- - Jacksonville
- - Panama City
Colorado
- - Colorado Springs
- - Denver
- - Lonetree
Alabama
- - Birmingham
- - Huntsville
Connecticut
- - Bridgeport
- - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,220 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
What the finished NCT01516541 record still lists
NCT01516541 is an interventional study that assigns participants to a tested intervention. Its 2,220 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01516541 names 20 study sites across 5 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01516541 about?
NCT01516541 is a clinical study titled "A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease". This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular dise...
What is the current status of trial NCT01516541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,220 participants. The study started on 2012-01. Estimated completion is 2012-07.
What conditions does trial NCT01516541 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD).
What interventions are being tested in trial NCT01516541?
The interventions under investigation include: Placebo (DRUG), Background care (OTHER), dalcetrapib (DRUG).
Who is sponsoring clinical trial NCT01516541?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01516541 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01516541's enrollment target sits among peer trials
2,220 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia